Coronary heart disease
Conditions
Interventions
Sponsors
Guang'anmen Hospital, China Academy of Chinese Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Follow the diagnostic criteria for unstable angina pectoris of coronary heart disease; 2. Patients who diagnosed with kidney deficiency and blood stasis syndrome by TCM syndromes; 3. Patients aged between 18 and 80 years; 4. Patients who voluntarily sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. Severe valvular heart disease, severe neurosis, menopausal syndrome, hyperthyroidism, cervical spondylosis, biliary heart disease, stomach and esophageal reflux and other non-coronary heart disease caused by chest pain; 2. Poor hypertension control (under drug control, blood pressure >=160/100mmHg at rest and occasionally within a week), severe cardiopulmonary insufficiency (EF<35%), severe arrhythmia (rapid atrial fibrillation, atrial flutter, paroxysmal ventricular tachycardia,atrioventricular block of type II and above, complete bundle branch block); 3. Complicated with serious primary diseases such as heart, brain, liver, kidney, hematopoietic system, (hepatic function ALT or AST value ?1.5 times the upper limit of normal, patients with abnormal renal function), insulin-dependent type 2 diabetes; 4. Patients with depression or anxiety; 5.Pregnant or lactating women; 6. Patients with malignant tumors; 7. Patients with allergies and allergies to test drug components; 8. Patients with poor compliance and low possibility of follow-up; 9. Participants in other clinical trials within the past month; 10. Other major diseases or factors that interfere with the completion of the trial or affect the interpretation of the results.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The effect of coronary heart disease and angina pectoris;The effect of TCM Syndromes of coronary heart disease and angina pectoris; | — |
Secondary
| Measure | Time frame |
|---|---|
| Stop and decrease of nitroglycerin;ECG efficacy;Seattle Angina Questionnaiire;Blood lipid efficacy;Cardiovascular endpoint;Safety evaluation; | — |
Countries
China
Contacts
Public ContactJie Wang
Guang'anmen Hospital, Chinese Academy of traditional Chinese Medicine
Outcome results
None listed